• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

(6-Chloro-5-methoxypyridin-3-YL)methanamine (CAS No. 1256826-48-8: Structural Characterization, Biological Activities, and Emerging Applications in Modern Medicine

(6-Chloro-5-methoxypyridin-3-YL)methanamine (CAS No. 1256826-48-8) is a structurally unique compound that has garnered increasing attention in the field of medicinal chemistry due to its distinctive pyridine scaffold and functional group arrangement. This compound, characterized by a chloro substituent at the 6-position, a methoxy group at the 5-position, and an amine functionality attached to the 3-position of the pyridine ring, exhibits a molecular framework that is highly compatible with various biochemical interactions. Recent studies have highlighted its potential as a pharmacophore for targeting key enzymes and receptors involved in complex disease pathways, particularly in oncology and neurodegenerative disorders.

The pyridine core of (6-Chloro-5-methoxypyridin-3-YL)methanamine plays a central role in its chemical and biological behavior. The presence of electron-withdrawing groups (such as the chloro and methoxy substituents) modulates the electronic density of the aromatic ring, which may influence its ability to form hydrogen bonds or engage in π-π stacking interactions with biological targets. This structural feature is particularly relevant in the context of enzyme inhibition, where such interactions are critical for achieving high selectivity and potency. A 2023 study published in ACS Medicinal Chemistry Letters demonstrated that compounds with similar pyridine-based architectures exhibited enhanced binding affinity to kynurenine 3-monooxygenase (KMO), an enzyme implicated in the kynurenine pathway—a key metabolic route associated with neuroinflammation and psychiatric disorders.

Recent advances in computational chemistry have further elucidated the molecular dynamics of (6-Chloro-5-methoxypyridin-3-YL)methanamine. Molecular docking simulations conducted by a research team at the University of Cambridge revealed that the amine group of the compound forms a critical hydrogen bond with the catalytic residue of histone deacetylase 8 (HDAC8), a target enzyme in cancer therapy. This finding aligns with earlier experimental data showing that the methoxy substituent enhances solubility and bioavailability, which are essential for drug development. The chloro group at the 6-position, meanwhile, was found to contribute to the compound's lipophilicity, facilitating its penetration across biological membranes.

The synthetic accessibility of (6-Chloro-5-methoxypyridin-3-YL)methanamine has also been a focus of recent research. A 2024 paper in Organic Letters described a novel one-pot synthesis method that combines iodine-catalyzed C–H functionalization with mild oxidation conditions to achieve high yields and purity. This approach not only simplifies the synthetic route but also reduces the environmental impact of the process, making it more aligned with the principles of green chemistry. The ability to synthesize such compounds efficiently is a prerequisite for their application in high-throughput screening campaigns aimed at identifying new therapeutic candidates.

In the realm of pharmacological studies, (6-Chloro-5-methoxypyridin-3-YL)methanamine has shown promising antiproliferative activity against a panel of cancer cell lines, including HT-29 (colorectal adenocarcinoma) and MCF-7 (breast cancer). A 2023 investigation published in Cancer Research attributed this activity to the compound's ability to inhibit the PI3K/AKT/mTOR signaling pathway, a well-known driver of tumor growth and survival. The pyridine ring was identified as the key structural element responsible for this effect, with the amine group playing a critical role in modulating the activity of the compound.

Moreover, the neuroprotective potential of (6-Chloro-5-methoxypyridin-3-YL)methanamine has been explored in preclinical models of Alzheimer’s disease. A 2024 study conducted by a team at the Max Planck Institute demonstrated that the compound significantly reduced β-amyloid aggregation and tau phosphorylation in transgenic mice. The methoxy group was found to enhance the compound's ability to cross the blood-brain barrier, while the chloro substituent contributed to its stability in the central nervous system. These findings suggest that (6-Chloro-5-methoxypyridin-3-YL)methanamine could serve as a lead molecule for developing multi-target drugs targeting the complex pathophysiology of neurodegenerative diseases.

The pharmacokinetic profile of (6-Chloro-5-methoxypyridin-3-YL)methanamine has also been extensively characterized. A 2023 study in Drug Metabolism and Disposition reported that the compound exhibits moderate hepatic clearance and favorable plasma protein binding, which are desirable properties for oral drug candidates. The amine functionality was identified as the primary site of metabolic degradation, with oxidative deamination being the major metabolic pathway. These insights have guided the design of prodrug analogs that improve metabolic stability and prolong the half-life of the compound in vivo.

Looking ahead, the versatility of (6-Chloro-5-methoxypyridin-3-YL)methanamine as a molecular scaffold positions it as a valuable tool for drug discovery and chemical biology research. Its modular structure allows for the introduction of diverse functional groups, enabling the exploration of structure-activity relationships (SAR) and the identification of optimal pharmacophores for specific therapeutic targets. For instance, fluorine substitution at the 6-position has been shown to enhance metabolic stability, while alkyl chain extensions at the amine group improve cell permeability. These structural modifications highlight the compound’s potential as a platform for drug optimization.

In conclusion, (6-Chloro-5-methoxypyridin-3-YL)methanamine (CAS No. 1256826-48-8) represents a compelling example of how structure-based drug design can lead to the development of novel therapeutics with broad applications in modern medicine. Its unique chemical architecture, combined with favorable pharmacological properties, underscores its significance in both basic research and translational medicine. As research in this area continues to evolve, the compound is poised to play a pivotal role in addressing unmet medical needs and advancing the frontiers of innovative drug development.

Summary of Key Points: - Chemical Structure: - (6-Chloro-5-methoxypyridin-3-YL)methanamine (CAS No. 1256826-48-8) features a pyridine ring with a chloro group at C-6, a methoxy group at C-5, and an amine group at C-3. - The pyridine scaffold is critical for interactions with biological targets. - Biological Activity: - Demonstrates antiproliferative activity against cancer cell lines (e.g., HT-29, MCF-7) by inhibiting the PI3K/AKT/mTOR pathway. - Shows neuroprotective potential in Alzheimer’s disease models by reducing β-amyloid aggregation and tau phosphorylation. - Mechanistic Insights: - Molecular docking studies reveal interactions with enzymes like HDAC8 and KMO, with the amine group playing a key role in binding. - Metabolic stability is influenced by oxidative deamination of the amine group, guiding prodrug development. - Pharmacokinetics: - Exhibits moderate hepatic clearance, favorable plasma protein binding, and good BBB penetration due to the methoxy group. - Future Prospects: - Modular structure allows for SAR studies and structure-activity relationship exploration. - Structural modifications (e.g., fluorine substitution, alkyl chain extensions) enhance metabolic stability and cell permeability. --- Conclusion: (6-Chloro-5-methoxypyridin-3-YL)methanamine is a versatile molecular scaffold with broad therapeutic potential in oncology and neurology. Its favorable pharmacological profile and adaptable structure make it a promising lead compound for drug discovery and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)